Precautionary marketing suspension of thalassaemia medicine Zynteglo

View source ↗

Summary

EMA announces a precautionary marketing suspension of Zynteglo, a gene therapy for thalassemia, pending further investigation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia

Drugs mentioned

• Zynteglo (luspogene nepogene)